Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; MandalĂ , Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Delord, Jean-Pierre; Robert, Caroline; Nyakas, Marta; McArthur, Grant A; Kudchakar, Ragini; Mahipal, Amit; Yamada, Yasuhide; Sullivan, Ryan J; Arance, Ana; Kefford, Richard F; Carlino, Matteo S; Hidalgo, Manuel; Gomez-Roca, Carlos; Michel, Daniela; Seroutou, Abdelkader; Aslanis, Vassilios; Caponigro, Giordano; Stuart, Darrin; Moutouh-de Parseval, Laure; Demuth, Tim; Dummer, Reinhard (2017). Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. Clinical Cancer Research:1-38.

Robert, Caroline; Dummer, Reinhard; Gutzmer, Ralf; Lorigan, Paul; Kim, Kevin B; Nyakas, Marta; Arance, Ana; Liszkay, Gabriella; Schadendorf, Dirk; Cantarini, Mireille; Spencer, Stuart; Middleton, Mark R (2013). Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncology, 14(8):733-740.

This list was generated on Mon Dec 11 18:37:31 2017 CET.